Pfizer announces positive top-line results from Phase 3 study of hemophilia B gene therapy candidate
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) today announced positive top-line results from the Phase 3 BENEGENE-2 study (NCT03861273) evaluating fidanacogene elaparvovec, an investigational gene therapy, for the treatment of adult males with moderately severe to severe hemophilia B.
VidPrevtyn Beta COVID-19 booster vaccine, developed by Sanofi and GSK, approved for use in Great Britain
- Details
- Category: GlaxoSmithKline
GSK plc (LSE/NYSE: GSK) has announced the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) authorised Sanofi's SARS-CoV-2 spike protein (B.1.351 strain) vaccine for the prevention of COVID-19 disease in adults aged 18 and above in Great Britain, following the European Commission licence last month, which included Northern Ireland.
Pfizer announces FDA and EMA acceptance of etrasimod regulatory submissions for ulcerative colitis
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for etrasimod for individuals living with moderately-to-severely active ulcerative colitis (UC). The FDA's decision is expected in the second half of 2023. The European Medicines Agency (EMA) has also accepted the Marketing Authorization Application (MAA) for etrasimod in the same patient population with the decision anticipated in the first half of 2024.
Recombinant adeno-associated virus (rAAV) technology pioneered by AskBio's Dr. Jude Samulski is key component of all FDA approved AAV gene therapeutics
- Details
- Category: Bayer
Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned and independently-operated subsidiary of Bayer AG, today announced that the FDA's approval of a new adeno-associated virus (AAV) gene therapy to treat adults with hemophilia B marks another milestone for the advancement of AAV therapeutics and highlights the important research contributions made by AskBio Co-Founder, President and Chief Scientific Officer, R. Jude Samulski, PhD.
Roche announces U.S. collaboration with Pfizer to help patients who test positive for COVID-19 navigate risks, symptoms, testing and treatment options
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has entered into a U.S. focused collaboration with Pfizer to drive awareness and educate on the importance of timely COVID-19 testing, available treatment options, symptoms and the high-risk factors that can increase the chance of progressing to severe illness.
GSK and Wave Life Sciences announce collaboration to drive discovery and development of oligonucleotide therapeutics focusing on novel genetic targets
- Details
- Category: GlaxoSmithKline
GSK plc (LSE/NYSE: GSK) and Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced a strategic collaboration to advance oligonucleotide therapeutics, including Wave's preclinical RNA editing programme targeting alpha-1 antitrypsin deficiency (AATD), WVE-006.
Bayer launches industry-first public database listing company's science collaborations and partnerships in the U.S.
- Details
- Category: Bayer
Bayer has announced the U.S. launch of the Bayer Science Collaboration Explorer (BSCE) as part of its ongoing efforts to enhance public trust in scientific innovations, processes, and R&D activities. The Explorer is a publicly accessible database where Bayer shares information on its science collaborations and new contracts with universities, public research institutions, and individuals.
More Pharma News ...
- Pfizer and Clear Creek Bio to collaborate on a research program targeting SARS-CoV-2 papain-like protease
- Bayer supports rebuilding of Ukrainian healthcare system by donating 1.3 million euros
- Eisai and Biogen announced the results from large global Phase 3 confirmatory Clarity AD clinical study of lecanemab
- AstraZeneca to acquire Neogene Therapeutics, accelerating ambition in Oncology cell therapy
- Pfizer and BioNTech report new data on Omicron BA.4/BA.5-adapted bivalent booster
- GSK announces positive Phase IIa study results for a new first-in-class candidate medicine for patients with tuberculosis
- Sanofi and GSK's next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission